BioCryst Pharmaceuticals, Inc.
BCRX
$8.39
-$0.17-1.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 12.24% | 10.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.24% | 10.64% | |||
| Cost of Revenue | 10.39% | -24.71% | |||
| Gross Profit | 12.99% | 36.51% | |||
| SG&A Expenses | 5.96% | 2.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.45% | -8.63% | |||
| Operating Income | 40.32% | 570.87% | |||
| Income Before Tax | 755.67% | 102.92% | |||
| Income Tax Expenses | 92.98% | -9.70% | |||
| Earnings from Continuing Operations | 15,790.63% | 100.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15,790.63% | 100.12% | |||
| EBIT | 40.32% | 570.87% | |||
| EBITDA | 39.69% | 986.07% | |||
| EPS Basic | 12,050.00% | 100.15% | |||
| Normalized Basic EPS | 1,282.61% | 102.94% | |||
| EPS Diluted | 19,900.00% | 100.08% | |||
| Normalized Diluted EPS | 1,277.27% | 102.81% | |||
| Average Basic Shares Outstanding | 0.30% | 0.72% | |||
| Average Diluted Shares Outstanding | 2.15% | 3.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||